Peking Union Medical College Hospital Archives

Norroy starts 600-patient Phase 3 trial of 177Lu-NYM032 in metastatic prostate cancer

Norroy Bioscience has started pivotal Phase 3 development of 177Lu-NYM032 in PSMA-positive metastatic castration-resistant prostate cancer, with a registered target enrollment of about 600 patients and overall survival as the primary objective.

Pharma & Biotech

Could utrophin become the next frontier in DMD care? Inside Ractigen’s RNAa push

by Pallavi Madhiraju
December 13, 2025
0 Comments

Ractigen Therapeutics has initiated human testing of RAG-18, a novel small activating RNA (saRNA) therapeutic candidate for Duchenne muscular dystrophy (DMD), by dosing the first patient in an investigator-initiated trial at Peking Union Medical College Hospital in Beijing. The study is being led by Professor Dai Yi, a recognized expert in neuromuscular disorders, and will